Indaptus TherapeuticsINDP -5.46%26 Market Cap is $402.01 Mil as of Jun. 25, 2026. GuruFocus rates INDP with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, Indaptus Therapeutics ranks better than 68.62% on this metric.
Indaptus Therapeutics's quarterly market cap
increased
from Sep. 2025 ($4.71 Mil) to Dec. 2025 ($6.31 Mil) and
increased
from Dec. 2025 ($6.31 Mil) to Mar. 2026 ($206.10 Mil).
Indaptus Therapeutics's annual market cap
declined
from Dec. 2023 ($14.78 Mil) to Dec. 2024 ($10.12 Mil) and
declined
from Dec. 2024 ($10.12 Mil) to Dec. 2025 ($6.31 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Indaptus Therapeutics's Enterprise Value for Today is $396.19 Mil.
Indaptus Therapeutics (NAS:INDP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Indaptus Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indaptus Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Indaptus Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Indaptus Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indaptus Therapeutics (INDP) has a Market Cap of $402.01 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Indaptus Therapeutics and its competitors. According to the industry distribution chart, Indaptus Therapeutics ranks #449 out of 1431 companies in the Biotechnology industry, placing it in the top 31.4%.
Is Indaptus Therapeutics' Market Cap too high?
Indaptus Therapeutics' current Market Cap is $402.01 Mil. The Biotechnology industry median Market Cap is 117.63. Indaptus Therapeutics' value of $402.01 Mil is 241.8% above this industry median. Based on the distribution chart, Indaptus Therapeutics ranks #449 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Indaptus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Indaptus Therapeutics' Market Cap compare to KPTI and NBP?
According to the Biotechnology industry distribution chart, Indaptus Therapeutics ranks #449 out of 1431 companies for Market Cap. This puts Indaptus Therapeutics in the upper half of its industry. The industry median Market Cap is 117.63. Indaptus Therapeutics' value of $402.01 Mil is 241.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indaptus Therapeutics's current Market Cap of $402.01 Mil is 241.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Indaptus Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indaptus Therapeutics's current Market Cap is $402.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indaptus Therapeutics stock overvalued right now?
Indaptus Therapeutics (INDP) has a current Market Cap of $402.01 Mil. The current Market Cap is $402.01 Mil and 241.8% above the Biotechnology industry median of 117.63. Indaptus Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Indaptus Therapeutics (INDP), the current Market Cap is $402.01 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
26GF Score
Get the complete analysis for INDP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDP has been successfully added to your 
